Aurinia Pharmaceuticals (AUPH)

• Market cap: $1.95B
• 1 day: 1.47%
• 5 days: 0.46%
• 1 month: -9.59%
• 3 months: -0.65%
• 6 months: 3.62%
• Year to date: -1.11%
• 1 year: 69.61%
• 5 years: 8.82%
• 10 years: 346.47%
• Sector: Healthcare
• Industry: Biotechnology

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Employees: 128